Yann Nguyen, Gabriel Baron, Naima Hamamouche, Rakiba Belkhir, Sylvie Miconnet, Martin Soubrier, Camille Hostachy, Pascale Thevenot, André Basch, Marie-Elise Truchetet, Pascal Claudepierre, Emmanuelle Dernis, Hubert Marotte, René-Marc Flipo, Olivier Brocq, Jacques Morel, Bruno Fautrel, Carine Salliot, Alain Saraux, Charles Leske, Thierry Schaeverbeke, Philippe Ravaud, Xavier Mariette, Adeline Ruyssen-Witrand, Raphaèle Seror
{"title":"短信/电子邮件提醒是否能提高抗肿瘤坏死因子类风湿关节炎患者的流感疫苗接种率：ART e-队列中的嵌套随机对照试验。","authors":"Yann Nguyen, Gabriel Baron, Naima Hamamouche, Rakiba Belkhir, Sylvie Miconnet, Martin Soubrier, Camille Hostachy, Pascale Thevenot, André Basch, Marie-Elise Truchetet, Pascal Claudepierre, Emmanuelle Dernis, Hubert Marotte, René-Marc Flipo, Olivier Brocq, Jacques Morel, Bruno Fautrel, Carine Salliot, Alain Saraux, Charles Leske, Thierry Schaeverbeke, Philippe Ravaud, Xavier Mariette, Adeline Ruyssen-Witrand, Raphaèle Seror","doi":"10.1093/rheumatology/keae599","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the effectiveness of short message service (SMS) and/or email reminders in improving influenza vaccination coverage rates among rheumatoid arthritis (RA) patients treated with anti-TNF therapies, and to identify factors associated with vaccination.</p><p><strong>Methods: </strong>A nested randomized controlled trial in the ART e-cohort, an ongoing French nationwide multicentre prospective cohort of RA patients treated with anti-TNF therapy. Patients were 1:1 randomized, with stratification on age. The intervention consisted in regular reminders via SMS and/or emails to get vaccinated against influenza during the vaccination campaign. After the end, all participants received a questionnaire. The primary outcome was the influenza vaccination coverage. Secondary outcomes included the vaccination coverage before and after COVID-19 pandemic, and factors associated with vaccination.</p><p><strong>Results: </strong>Between October 2021 and April 2022, 446 participants were randomized (224 in the intervention group, 222 in the control group). Among them, 325 (73%) reported their vaccination status and 221 (68%) were vaccinated against influenza: 116/158 (73%) in the intervention group, vs 105/167 (63%) in the control group (RR 1.08; 95% CI 0.95-1.23). The vaccination coverage before and after COVID-19 pandemic did not differ (72% vs 72%; 95% CI -8% to8%). Age ≥65 years (OR 6.25; 95% CI 2.88-13.60), and previous influenza vaccination in the years before inclusion (OR 7.81; 95% CI 4.36-14.02) were associated with higher rates of vaccination.</p><p><strong>Conclusion: </strong>SMS and/or e-mails reminders did not significantly improve influenza vaccination rates in our cohort. COVID-19 pandemic did not substantially impact the influenza vaccination coverage. Our results might be counterbalanced by an already high vaccination coverage.</p><p><strong>Trial registration number: </strong>www.clinicaltrials.gov; NCT05220423; NCT03062865.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort.\",\"authors\":\"Yann Nguyen, Gabriel Baron, Naima Hamamouche, Rakiba Belkhir, Sylvie Miconnet, Martin Soubrier, Camille Hostachy, Pascale Thevenot, André Basch, Marie-Elise Truchetet, Pascal Claudepierre, Emmanuelle Dernis, Hubert Marotte, René-Marc Flipo, Olivier Brocq, Jacques Morel, Bruno Fautrel, Carine Salliot, Alain Saraux, Charles Leske, Thierry Schaeverbeke, Philippe Ravaud, Xavier Mariette, Adeline Ruyssen-Witrand, Raphaèle Seror\",\"doi\":\"10.1093/rheumatology/keae599\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To evaluate the effectiveness of short message service (SMS) and/or email reminders in improving influenza vaccination coverage rates among rheumatoid arthritis (RA) patients treated with anti-TNF therapies, and to identify factors associated with vaccination.</p><p><strong>Methods: </strong>A nested randomized controlled trial in the ART e-cohort, an ongoing French nationwide multicentre prospective cohort of RA patients treated with anti-TNF therapy. Patients were 1:1 randomized, with stratification on age. The intervention consisted in regular reminders via SMS and/or emails to get vaccinated against influenza during the vaccination campaign. After the end, all participants received a questionnaire. The primary outcome was the influenza vaccination coverage. Secondary outcomes included the vaccination coverage before and after COVID-19 pandemic, and factors associated with vaccination.</p><p><strong>Results: </strong>Between October 2021 and April 2022, 446 participants were randomized (224 in the intervention group, 222 in the control group). Among them, 325 (73%) reported their vaccination status and 221 (68%) were vaccinated against influenza: 116/158 (73%) in the intervention group, vs 105/167 (63%) in the control group (RR 1.08; 95% CI 0.95-1.23). The vaccination coverage before and after COVID-19 pandemic did not differ (72% vs 72%; 95% CI -8% to8%). Age ≥65 years (OR 6.25; 95% CI 2.88-13.60), and previous influenza vaccination in the years before inclusion (OR 7.81; 95% CI 4.36-14.02) were associated with higher rates of vaccination.</p><p><strong>Conclusion: </strong>SMS and/or e-mails reminders did not significantly improve influenza vaccination rates in our cohort. COVID-19 pandemic did not substantially impact the influenza vaccination coverage. Our results might be counterbalanced by an already high vaccination coverage.</p><p><strong>Trial registration number: </strong>www.clinicaltrials.gov; NCT05220423; NCT03062865.</p>\",\"PeriodicalId\":21255,\"journal\":{\"name\":\"Rheumatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2024-11-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/rheumatology/keae599\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/rheumatology/keae599","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的评估短信服务（SMS）和/或电子邮件提醒在提高接受抗肿瘤坏死因子疗法治疗的类风湿性关节炎（RA）患者流感疫苗接种率方面的效果，并确定与疫苗接种相关的因素：在 ART e-cohort 中进行嵌套随机对照试验，AR e-cohort 是一项正在进行中的法国全国性多中心前瞻性队列，对象是接受抗肿瘤坏死因子治疗的 RA 患者。患者按 1:1 随机分配，并根据年龄进行分层。干预措施包括在疫苗接种活动期间通过短信和/或电子邮件定期提醒患者接种流感疫苗。活动结束后，所有参与者都会收到一份调查问卷。主要结果是流感疫苗接种覆盖率。次要结果包括 COVID-19 大流行前后的疫苗接种率以及与疫苗接种相关的因素：2021 年 10 月至 2022 年 4 月期间，446 名参与者被随机分组（干预组 224 人，对照组 222 人）。其中 325 人（73%）报告了自己的疫苗接种情况，221 人（68%）接种了流感疫苗：干预组 116 人/158 人（73%），对照组 105 人/167 人（63%）（RR 1.08；95% CI 0.95-1.23）。COVID-19 大流行前后的疫苗接种率没有差异（72% vs 72%; 95% CI -8%-8%）。年龄≥65岁（OR 6.25; 95% CI 2.88-13.60）和在纳入前几年曾接种过流感疫苗（OR 7.81; 95% CI 4.36-14.02）与较高的疫苗接种率有关：结论：在我们的队列中，短信和/或电子邮件提醒并未显著提高流感疫苗接种率。COVID-19大流行并未对流感疫苗接种率产生重大影响。我们的结果可能会被已经很高的疫苗接种率所抵消。试验注册号：www.clinicaltrials.gov; NCT05220423; NCT03062865。
Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort.
Objectives: To evaluate the effectiveness of short message service (SMS) and/or email reminders in improving influenza vaccination coverage rates among rheumatoid arthritis (RA) patients treated with anti-TNF therapies, and to identify factors associated with vaccination.
Methods: A nested randomized controlled trial in the ART e-cohort, an ongoing French nationwide multicentre prospective cohort of RA patients treated with anti-TNF therapy. Patients were 1:1 randomized, with stratification on age. The intervention consisted in regular reminders via SMS and/or emails to get vaccinated against influenza during the vaccination campaign. After the end, all participants received a questionnaire. The primary outcome was the influenza vaccination coverage. Secondary outcomes included the vaccination coverage before and after COVID-19 pandemic, and factors associated with vaccination.
Results: Between October 2021 and April 2022, 446 participants were randomized (224 in the intervention group, 222 in the control group). Among them, 325 (73%) reported their vaccination status and 221 (68%) were vaccinated against influenza: 116/158 (73%) in the intervention group, vs 105/167 (63%) in the control group (RR 1.08; 95% CI 0.95-1.23). The vaccination coverage before and after COVID-19 pandemic did not differ (72% vs 72%; 95% CI -8% to8%). Age ≥65 years (OR 6.25; 95% CI 2.88-13.60), and previous influenza vaccination in the years before inclusion (OR 7.81; 95% CI 4.36-14.02) were associated with higher rates of vaccination.
Conclusion: SMS and/or e-mails reminders did not significantly improve influenza vaccination rates in our cohort. COVID-19 pandemic did not substantially impact the influenza vaccination coverage. Our results might be counterbalanced by an already high vaccination coverage.
期刊介绍：
Rheumatology strives to support research and discovery by publishing the highest quality original scientific papers with a focus on basic, clinical and translational research. The journal’s subject areas cover a wide range of paediatric and adult rheumatological conditions from an international perspective. It is an official journal of the British Society for Rheumatology, published by Oxford University Press.
Rheumatology publishes original articles, reviews, editorials, guidelines, concise reports, meta-analyses, original case reports, clinical vignettes, letters and matters arising from published material. The journal takes pride in serving the global rheumatology community, with a focus on high societal impact in the form of podcasts, videos and extended social media presence, and utilizing metrics such as Altmetric. Keep up to date by following the journal on Twitter @RheumJnl.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
